Antibe Therapeutics Inc(Pre-Merger) ATBPF

Lots of Questions

[Duster340]

but no answers = uncertainty and a lower stock price

[Harper75]

IMO the total silence from Antibe leadership is astounding.   

[Montana5]

Insider buys March 6/7: Curtis 15,000 shares @ $.52 Legault 20,000 shares @ $.50 Stauffer 24,000 shares @ $.40 USD Not exactly mortgaging the house, but better than nothing. Curious as to where they are coming up with $24 million USD to settle with Nuance and the timing of that payment. Makes no sense doing a financing at the current share price. Hopefully they can come with a viable option. Open

[MrMugsy]

Still here -  trying to understand all the options and what it takes to get P2 completed.

[Duster340]

all options maybe running out, if payment to nuance is do within weeks of the ruling that means they will be broke no money for P2 and not even enough cash left to keep the lights on at the office. i think the insider buying was just an effort to stabilize the stock price while they try and find someone to finance them, if the stock were to collapses down to a dime financing would be impossible.

[Montana5]

Maybe with the way ATE respectfully waived the white flag on the arbitration, could it be possible that Nuance might be agreeable to a graduated payback that might benefit the completion of P2 and the potential of securing a new partnership agreement? We know the amount of the settlement, but under what terms and conditions? I'm hoping ATE will be providing more information this week with

[Duster340]

anything is possible but is nuance willing to take that risk unlikely, if they did agree to a deal that kicks payment down the road antibe will burn through the cash with P2 but what if otena is unsuccessful ATE will be bankrupt and nuance will also lose out on there 24M that they have in the bag right now.

[MrMugsy]

Many unknowns about how this moves forward. Nuance is an unsecured creditor but I don't know what happens after that. I think we're waiting for them to chat first. I don't know what follows.